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ABSTRACTS
1
Exacerbation or new-onset of Psoriasis with TNF inhibitor therapy: An analysis
and review of cases from 1990 through 2007
J.F. Kerbleski, A. Gottlieb Dermatology, Tufts Medical Center, Boston, MA
Tumor necrosis factor (TNF) inhibitors have well known but rare adverse effects including
infections, malignancies, and induction of autoimmune conditions. Interesting among these
reports are cases of exacerbation or new-onset of psoriasis with TNF inhibitor therapy as they are
an approved treatment of this condition. Objective is to analyze published cases of psoriasis
occurring during TNF blockade therapy and to provide an overview of proposed etiologies and
treatment recommendations.A literature search using PubMed and Ovid MEDLINE was
performed for articles published between January 1990 and September 2007 regarding reported
cases of psoriasis in patients receiving therapy with TNF blocking agents. 127 total cases of
psoriasis were identified—70 with infliximab (55%), 35 with etanercept (28%), and 22 in patients
on adalimumab (17%). The majority of primary conditions in these patients were rheumatoid
arthritis (50.4%), ankylosing spondylitis (16.1%), and Crohn’s disease (13.0%); ankylosing
spondylitis and Behcet’s disease (1.5%), however, were disproportionately higher represented.
Females comprised almost 60% of cases; mean age of reported patients was 45.8, and the time
from initiation of treatment to onset of lesions averaged 10.5 months. The types of reported
psoriasis varied: palmoplantar pustular psoriasis was observed in over 40% of the cases, plaque-
type psoriasis in 33%, and other types comprising the remainder. Histology was only confirmed in
40% of cases. Various treatment options were employed with mixed results. Topical cortico-
steroids were used in 70 cases but led to resolution in only 25% of reports when used alone.
Changing to a different TNF inhibitor led to resolution in just 15% of cases. Stopping the anti-TNF
agent and starting systemic therapy was most effective and led to resolution in over 64% of
cases.More reports and information are needed. Biopsies of these psoriatic lesions occurring in
TNF inhibitor therapy may reveal what cell types and cytokines drive this development.
Additionally, a treatment algorithm is needed for this paradoxical adverse effect of therapy with
TNF inhibitor therapy.
3
Sebaceous Neoplasms and the incidence of associated internal malignancies
B Lee1, L. Yu2, L. Ma3, D. Lu4 1Dermatology, Washington University, St Louis, MO, 2Pathology,
University of Michigan, Ann Arbor, MI, 3Dermatology and Pathology, University of Michigan,
Ann Arbor, MI and 4Pathology, Washington University, St Louis, MO
The rare association between visceral malignancies and sebaceous gland neoplasms was first
described by Muir et al. in 1967 and Torre et al. in 1968. Currently, it is believed that there are
two types of Muire-Torre syndrome(MTS); one an autosomal-dominant genetic disease with
defects in mismatch repair genes, considered by many to be a variant of Hereditary Non-
Polyposis Colon Cancer Syndrome (HNPCC), and the other with an undefined pathogenesis. In
1984, Finan and Connolly published a case series evaluating the incidence of visceral malignancy
in patients with sebaceous gland neoplasms. They discovered that among 59 patients, 42% had
an associated primary visceral malignancy, 50% of which were colonic in origin. The current
recommendation is to screen all patients for cancer in the presence of a single sebaceous tumor.
However, there are discrepancies in the types of studies necessary, and the frequency suggested.
Because there has been only one case series to date, the aim of our study was to investigate the
prevalence and breadth of internal malignancies associated with sebaceous neoplasms, and
surveillance practices by physicians. Study design: Multicenter cohort study. We performed a
computer search to identify patients with sebaceous tumors, such as sebaceous adenoma,
sebaceoma, and sebaceous carcinoma diagnosed at two university hospital systems. Relevant
clinical information was obtained via chart review and database searches. Results: A total of 93
patients with sebaceous neoplasms and available clinical records were identified. Of these, 23
(25%) were found to have visceral malignancies, 27 (29%) had other findings such as colonic
polyps and visceral adenomas, and 13 (57%) of these patients had a family history of carcinoma.
Despite screening recommendations, only 16 (17%) patients had associated cancer screening.
Conclusions: These findings suggest a high incidence of internal malignancy associated with
sebaceous neoplasms. While 56% of patients with visceral findings had gastrointestinal tumors
and/or polyps, 37% of malignancies were urogenital in origin, and 19% were either breast or lung
carcinoma, making it difficult to recommend a specific cancer work-up. Thus, it is important to be
aware of the range of potentially associated internal malignancies and to remain vigilant in
screening for Muir-Torre syndrome.
2
Zeaxanthin as an oral sunscreen: A pilot study in 17 patients
J. Graves1, D. Smith2, L. Cornelius3, M. Heffernan4 1,3Washington University, St Louis, MO,
2Private Practice and 3Wright State University, Dayton, OH
An orally administered sunscreen would have obvious benefits. Several studies have shown that
supplementation with high doses of carotenoids can protect against UV-induced erythema. We
sought to evaluate the efficacy of the carotenoid zeaxantin as an orally administered sunscreen.
17 healthy adult subjects with Fitzpatrick skin types I, II, or III received 12 weeks of
supplementation with zeaxanthin—10mg daily for 8 weeks followed by 30mg daily for 4 weeks.
The minimal erythema dose (MED) of broadband UVB was determined at baseline, and weeks 4,
8, and 12. The mean MED was 58% higher at week 12 as compared to baseline (Po0.01),
corresponding to a sun protection factor (SPF) of 1.58. The mean SPF after 8 weeks was 1.49 and
after 4 weeks was 1.20. The SPF of zeaxanthin after 12 weeks of supplementation was modest and
appeared to be comparable to that of other carotenoids.1 With such modest SPF’s, it is unlikely
that oral carotenoids would be adequate substitutes for topical sunscreens. However, they may be
very helpful as adjuncts, working synergistically to reduce oxidative damage caused by UV
radiation.
4
Clinical features associated with risk of Psoriatic Arthritis in Psoriasis patients
R. Soltani-Arabshahi1, B.Wong2, B. J. Feng3, S. Ahmed4, D.E. Goldgar5, K. Callis6, G.G. Krueger7
1,3-7Dermatology, University of Utah and 2College of Nursing, University of Utah
Psoriatic arthritis (PsA) affects 5–40% of patients with psoriasis. Determining features that predict
development of PsA is critical to timely treatment and prevention of long term associated
morbidity. We set out to study the clinical features of psoriasis that predict development of PsA in
a large psoriasis cohort.
Patients enrolled in the Utah Psoriasis Initiative from November 2002 to October 2008 (943
subjects; 50.2% female, 49.8% male; mean age 47.89±16.69) were included in the study. Cox
proportional hazards regression analysis was used to study factors affecting risk of PsA. Age of
onset of PsA was used as the time to event variable. Covariates included gender, age of onset of
psoriasis, family history of psoriasis, disease severity (measured as worst-ever involved body
surface area), Koebner phenomenon, nail involvement, body mass index (BMI) at enrollment,
patient reported BMI at age 18, and tobacco use. Variables with a P-value o0.05 were
considered significant in the final stepwise multivariate model.
Psoriatic arthritis was seen in 250 (26.5%) of patients with psoriasis. The mean age of onset was
27.17±16.54 for psoriasis and 37.09±14.66 for PsA. Patients who were overweight
(25pBMIo30) or obese (BMIX30) at age 18 had a higher risk of PsA (OR¼ 1.59, P¼ 0.029
for overweight and OR¼ 2.69, P¼ 0.005 for obese compared to normal BMI). Patients with an
earlier age of onset of psoriasis (earlier than 20 years-old) were more likely to develop PsA
(OR¼ 2.105; Po0.001). Other variables associated with increased risk of PsA in the multivariate
analysis included nail involvement (OR¼1.94; P¼0.001) and positive Koebner phenomenon
(OR¼ 1.58; P¼ 0.007). Smoking was not predictive of PsA (P¼ 0.582).
This study suggests that obesity in early adulthood increases the risk of developing PsA. In
addition, patients who develop psoriasis at an earlier age are more likely to develop arthritis than
patients with late-onset psoriasis. Obesity is increasingly being recognized as a pro-inflammatory
state. Increased adiposity is associated with higher levels of inflammatory cytokines known to be
associated with psoriasis, and this inflammatory milieu could be increasing the risk of psoriatic
arthritis. It logically follows that the prevention and treatment of obesity may decrease the risk of
PsA, particularly in patients with younger age of onset of psoriasis.
1840 Journal of Investigative Dermatology (2009), Volume 129
ABSTRACTS
5
International multi-centre Psoriasis and Psoriatic Arthritis reliability trial
(GRAPPA-IMPART): Assessment of skin, joints, nails and Dactylitis
A. Garg1, V. Chandran2, A. Gottlieb3, R.J. Cook4, K. Callis Duffin5, P. Helliwell6, A. Kavanaugh7,
G.G. Kreuger8, R. Langley9, C. Lynde10, N. McHugh11, P. Mease12, I. Olivieri13, P. Rahman14,
C.F. Rosen15, C. Salvarani16, D. Thaci17, S.M.A. Toloza18, M. Wong19, Q. Zhou20, D.D.
Gladman21, 1Boston University, Boston, MA, 2,18,19,21Toronto Western Hospital, Toronto,
Ontario, Canada, 3Tufts Medical Center,Boston, MA, 4,20University of Waterloo,Waterloo,
Ontario, Canada, 5,8University of Utah, Salt Lake City, UT, 6University of Leeds, Leeds, UK,
7University of California San Diego, San Diego, CA, 9Dalhousie University, Halifax, Nova Scotia,
Canada, 10,15,21University of Toronto,Tononto, Ontario, Canada, 11 University of Bath, Bath, UK,
12University of Washington School of Medicine, Seattle, WA, 13San Carlo Hospital of Potenza
and Madonna delle Grazie Hospital of Matera, 14Clare’s Mercy Hospital, St John’s, Newfound-
land, 16Arcispedale Santa Maria Nuova, 17Goethe University,Frankfort, Germany
Clinical trials in psoriasis and psoriatic arthritis (PsA) involve assessment of skin and joints. This study
aimed to determine whether the assessment of skin and joints in patients with PsA by rheumatologists
and dermatologists is reproducible.
10 rheumatologists and 9 dermatologists from 7 countries met for a combined physical
examination exercise to assess 20 PsA patients (11 males, mean age 51 years, mean PsA duration
11 years). Each physician assessed 10 patients according to a modified Latin square design that
enabled assessment of patient, assessor and order effect. Tender joint count [TJC], swollen joint
count [SJC], dactylitis, Physician’s Global Assessment of PsA disease activity (PGA-PsA), psoriasis
body surface area (BSA), Psoriasis Area and Severity Index (PASI), Lattice System Physician’s
Global Assessment of Psoriasis (LS-PGA), National Psoriasis Foundation Psoriasis Score (NPF-PS),
modified Nail Psoriasis Severity Index (mNAPSI), number of fingernails with nail changes (NN)
and Physician’s Global Assessment of psoriasis activity (PGA-Ps) were assessed. Variance
components analyses were carried out to estimate the intra-class correlation coefficient (ICC)
adjusted for order of measurements. There is excellent agreement (ICCX0.80) on mNAPSI,
substantial agreement (0.6XICCo0.80) on TJC, PASI, and NN, moderate agreement (0.4XIC-
Co0.60) on PGA-Ps, LS-PGA, NPF-PS and BSA and fair agreement (0.2XICCo0.40) on SJC,
dactylitis and PGA-PsA. The only measure that showed a significant difference between
dermatologists and rheumatologists was dactylitis (P¼ 0.0005). There is substantial-to-excellent
agreement on TJC, PASI, NN and mNAPSI among rheumatologists and dermatologists.
7
Insurance eligibility in Psoriasis compared to other major chronic illnesses
E. Seidler, A. Kimball Massachusetts General Hospital, Boston, MA
Like other chronic diseases, psoriasis is burdensome not only in its physical discomfort, but also in
its psychosocial impacts on patients’ occupational choices, social relationships and psychological
health. The consequences of coping with these burdens may ultimately lead to disability and a
decline in daily functioning that require patients to obtain health insurance designated for
disabled and/or low-income patients. We examined health insurance rates in the Partners
HealthCare system, consisting of 3,509,083 patients aged 18 and older at Massachusetts General
and Brigham and Women0s Hospitals. We compared rates in the general population to rates in
patients with psoriasis, dermatitis, arthritis, heart failure, diabetes type 2, hypertension, chronic
lung disease, depression, post-myocardial infarction and cancer. We found that rates of Medicaid,
Free Care or MassHealth in patients aged 18 and older were significantly higher than in the
general population (Po0.001). We also found a significant difference between psoriasis patients
aged 18–64 with Medicare or Medicaid, Free Care or MassHealth and the general population
(Po0.001). Furthermore, we validated the use of these insurance rates as surrogate measures of
disability in psoriasis patients and patients with other chronic diseases. We correlated these rates
to disability scores found by Rapp et al. in 1999 and found that health insurance rates in different
chronic diseases correlated to physical and mental disability scores with R-squared values40.60
(Po0.05). We conclude that psoriasis patients have greater physical and mental disability than
the general population as demonstrated by higher rates of subscription to health insurance plans
for low-income and disabled populations. This underscores the socioeconomic burdens of this
disease. Furthermore, these insurance rates may serve as important surrogate measures of
disability in chronic disease populations.
6
Association of new keratinocyte carcinomas with quality of life in a high-risk
population
K.C. Lee1, M. Weinstock2, 1Northwestern University, Chicago, IL and 2Brown VA Medical
Center, Providence, RI
Keratinocyte carcinomas (KCs) comprise the most common malignancy in the United States.
Quality of life (QoL) factors are important due to high risks of recurrence and the chronicity of
associated syndromes such as actinic keratoses (AKs). A previous cross-sectional study found the
presence of AKs associated with worse QoL, whereas a history of KCs had no independent
association. We sought to determine QoL differences with the development of new KCs and
increased counts of AKs. The VATTC was a randomized, double-blinded trial of topical tretinoin
0.1% for prevention of keratinocyte carcinoma, which followed a high-risk population for up to 6
years. All participants were diagnosed with at least 2 KCs in the prior 5 years, but were free of KCs
at enrollment. At baseline and every 12-months, the Skindex-29 was used to measure QoL in the
emotions, functioning, and symptoms domains. Six additional items were used to assess aspects
of QoL pertaining to KC-related worry/bother. At each follow-up visit, a dermatologist examined
the patient for AKs and KCs on the face and ears. The location of KCs was categorized based on a
standardized body chart–upper face, lower face, ear, eye, nose, or other. Analyses used t-tests,
analysis of variance, univariate and multivariate regression. Data from 799 participants enrolled
in the VATTC trial in 5 centers was analyzed. Participants were largely male, elderly, and
Caucasian. Approximately 50% of participants had increased AK counts at 12-months compared
to baseline; 25% had an increase of 4 or more. Likewise, 31% had a decrease in AK counts; 12%
had a decrease of 4 or more. These changes in AK counts were similar at 24- and 36-months
compared to the prior year. Neither development of KCs, nor increased AK counts were
associated with a QoL difference when patients’ Skindex scores were compared to their own
scores 12-months prior. The upper face was the most common area in which KCs developed (55,
56, and 52% at 12-, 24-, and 36-months, respectively). Location of KC did not affect QoL.
However, new KCs were independently associated with increased worry/bother items at 12-
months (Po0.01), but not at 24- or 36-months. These findings suggest that development of new
KCs or increased AK count does not change QoL, measured by Skindex, in this population with
multiple prior KCs. The Skindex-29 may be insufficiently sensitive at measuring QoL factors for
KCs, or QoL may not be substantially influenced by new KCs in this population.
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